Melanotan I (10 mg Vial) Dosage Protocol
Contents
- Quickstart Highlights
- Dosing & Reconstitution Guide
- Standard / Gradual Approach (3.0 mL = 3.33 mg/mL)
- Reconstitution Steps
- Supplies Needed
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Potential Benefits & Side Effects
- Lifestyle Factors
- Injection Technique
- Recommended Source
- Important Note
- References
Quickstart Highlights
Melanotan I is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH), primarily studied for its role in increasing skin pigmentation. It has also been observed to influence libido and erectile response due to melanocortin receptor activity.
This protocol outlines a gradual subcutaneous dosing approach designed to minimize common side effects such as nausea and flushing while achieving consistent pigmentation results.
- Reconstitution: Add 3.0 mL bacteriostatic water → 3.33 mg/mL
- Typical Dose Range: 250–1000 mcg daily
- Measurement: 1 unit (U-100 syringe) = ~33.3 mcg
- Storage:
- Lyophilized: −20°C
- Reconstituted: 2–8°C (use within 1–2 weeks)
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Titration (3 mL = 3.33 mg/mL)
| Week / Phase | Daily Dose | Units (U-100) | Volume |
|---|---|---|---|
| Week 1 | 250 mcg | 7.5 units | 0.075 mL |
| Week 2 | 500 mcg | 15 units | 0.15 mL |
| Week 3 | 750 mcg | 22.5 units | 0.225 mL |
| Weeks 4–8 | 1000 mcg | 30 units | 0.30 mL |
Maintenance (After Week 8):
500–1000 mcg 1–2× weekly (15–30 units)
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water using a sterile syringe
- Inject slowly into the vial (avoid foam formation)
- Gently swirl—do not shake
- Store refrigerated and protected from light
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
- Peptide Vials (Melanotan I, 10 mg each):
- 8 weeks ≈ 5 vials (~45–50 mg total)
- 12 weeks ≈ 8 vials (~70–75 mg total)
- 16 weeks ≈ 10 vials (~95–100 mg total)
- Insulin Syringes (U-100, 1 mL):
- Per week (daily dosing): 7 syringes
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- 12 weeks (8 vials): 24 mL → 3 × 10 mL bottles
- 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Protocol Overview
- Goal: Enhance skin pigmentation via melanocortin receptor activation
- Schedule: Daily injections for 6–8 weeks (loading phase)
- Maintenance: 1–2 injections per week
- Dose Range: 250–1000 mcg daily
- Cycle Length: 8–12 weeks typical
Dosing Protocol
- Start at 200–250 mcg daily
- Increase gradually every 1–2 weeks
- Target 500–1000 mcg daily by Weeks 4–8
- Transition to maintenance dosing after initial phase
- Inject at a consistent time and rotate sites
Storage Instructions
- Lyophilized: Store at −20°C in a dry, dark environment
- Reconstituted: Refrigerate at 2–8°C
- Avoid repeated freeze–thaw cycles
- Use within 2–3 weeks for best stability
- Allow vial to reach room temperature before opening
Important Notes
Key considerations for consistency, handling, and research accuracy.
- Always use a new, sterile insulin syringe for each administration; do not reuse needles
- Follow proper aseptic technique: clean both the vial stopper and injection site with separate alcohol swabs and allow to dry fully
- Rotate injection sites (abdomen, thighs, upper arms) to reduce irritation and avoid tissue buildup
- Administer injections slowly and steadily, allowing a few seconds before withdrawing the needle
- Keep a record of dosing, timing, and injection sites to maintain consistency throughout the protocol
- Do not use the solution if it appears cloudy, discolored, or contains visible particles
- Store and handle peptides according to recommended conditions to preserve stability
How This Works
Melanotan I works by activating melanocortin-1 receptors (MC1R) in melanocytes.
- Stimulates melanin production
- Enhances pigmentation pathways
- Supports UV-independent tanning research
- Provides more selective receptor targeting compared to MT-II
Potential Benefits & Considerations
Potential Benefits
- Increased skin pigmentation without heavy UV exposure
- Faster tanning response
- Maintenance dosing helps sustain results
Common Side Effects
- Nausea (most common)
- Facial flushing
- Reduced appetite
- Fatigue
- Injection site irritation
Serious Risks & Warnings
- Not FDA-approved
- Possible changes in moles or pigmentation
- Cardiovascular stimulation at higher doses
- High-dose toxicity risks (avoid excessive dosing)
Lifestyle Factors
- Use sun protection even if tanning increases
- Stay well hydrated
- Monitor skin and moles regularly
- Maintain disciplined dosing (avoid overuse)
Injection Technique
General guidance for subcutaneous administration:
- Clean the vial stopper and injection area with alcohol and allow to dry
- Gently pinch the skin and insert the needle at a 45–90° angle
- Inject slowly and steadily without aspirating
- Hold the needle in place for a few seconds before removing
- Rotate injection sites (abdomen, thighs, upper arms) to reduce irritation
Recommended Source
We recommend Fit Aminos for high-purity research peptide products.
Why Fit Aminos?
- High-purity, lab-tested peptide batches with quality verification.
- Consistent handling and preparation processes designed to support reliable research protocols.
- Transparent sourcing and dependable fulfillment for research-grade compounds.
Important Note
This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment. Melanoton I – 10mg remains an investigational peptide with limited human clinical data. For research use only. Not for human consumption.
References
PubMed — Dorr RT et al. (1996) — Phase I clinical study of melanotan-II, evaluation of dosing and safety in healthy volunteers
International Peptide Society — Melanotan II Monograph — Comprehensive peptide monograph covering dosing protocols and titration guidance
DermNet NZ — Melanotan II Information for Patients — Clinical dermatology guidance on melanotan use, side effects, and maintenance dosing
PubMed — Nelson ME et al. (2012)
— Case report: Melanotan II injection resulting in systemic toxicity and rhabdomyolysis
RxList — Melanotan-II Uses, Side Effects and Dosing
— Medical database overview of melanotan-II pharmacology and clinical effects